Jorge Monge

5PUBLICATIONS
42CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Regenerative medicine (incl. stem cells)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Mar 26, 2026
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma.

Shaji Kumar, Sundar Jagannath, Katja C Weisel

|May 22, 2024
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma.

Mateo Mejia Saldarriaga, Darren Pan, Caitlin Unkenholz

|Mar 05, 2024
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.

Meera Mohan, Jorge Monge, Nishi Shah

|Mar 05, 2024
Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study.

Zimu Gong, Godsfavour Umoru, Jorge Monge

|Apr 19, 2023
Two p53s in a Pod: Co-occurring plasma cell myeloma and therapy-related myeloid neoplasm following lenalidomide therapy.

Jorge Monge, Meri Razavi, Liming Bao

Pageof 1

Frequent Collaborators

2 joint publications

Nishi Shah

2 joint publications

Rajshekhar Chakraborty

2 joint publications

Carolina Schinke

2 joint publications

Meera Mohan